Associate Professor Sandra Turner

Clinical Associate Professor
Medicine, Westmead Clinical School

Telephone 98455200

Map

Selected grants

2013

  • Evaluating the Utility of a Patient Decision Aid for Prospective Participants in the TROG RAVES Prostate Cancer Trial (TROG 08.03); Sundaresan P, Bell M, Kneebone A, Turner S, Butow P; Prostate Cancer Foundation of Australia/Young Investigator Grants.

2011

  • A randomised controlled trial testing a Decision Aid to promote informed consent and recruitment to the TROG RAVES trial of post-prostatectomy radiotherapy; Turner S, Butow P, Juraskova I, Kneebone A, Woo H, Bell M; Royal Australian and New Zealand College of Radiologists/Research Support.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Denham, J., Steigler, A., Tai, K., Joseph, D., Matthews, J., Atkinson, C., Spry, N., Turner, S., North, J., Christie, D., et al (2013). Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiotherapy and Oncology, 107(2), 123-128. [More Information]
  • Smith, A., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(11), 2557-2564. [More Information]
  • Hindson, B., Turner, S., Millar, J., Foroudi, F., Gogna, N., Skala, M., Kneebone, A., Christie, D., Lehman, M., Wiltshire, K., et al (2012). Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. Journal of Medical Imaging and Radiation Oncology, 56(1), 18-30. [More Information]
  • Ng, E., Woo, H., Turner, S., Leong, E., Jackson, M., Spry, N. (2012). The Influence of Testosterone Suppression and Recovery on Sexual Function in Men With Prostate Cancer: Observations From a Prospective Study in Men Undergoing Intermittent Androgen Suppression. The Journal of Urology, 187(6), 2162-2167. [More Information]
  • Sundaresan, P., Turner, S., Kneebone, A., Pearse, M., Butow, P. (2011). Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03). Radiotherapy and Oncology, 101(3), 521-524. [More Information]
  • Denham, J., Steigler, A., Lamb, D., Joseph, D., Turner, S., Matthews, J., Atkinson, C., North, J., Christie, D., Spry, N., et al (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology, 12(5), 451-459. [More Information]
  • Turner, S., Morgan, G., Palme, C., Veness, M. (2010). Metastatic cutaneous squamous cell carcinoma of the external ear: a high-risk cutaneous subsite. Journal of Laryngology and Otology, 124(1), 26-31. [More Information]
  • Graham, P., Capp, A., Delaney, G., Goozee, G., Hickey, B., Turner, S., Browne, L., Milross, C., Wirth, A. (2006). A Pilot Randomised Comparison of Dexamethasone 96 mg vs 16 mg per day for Malignant Spinal-cord Compression Treated by Radiotherapy: TROG 01.05 Superdex Study. Clinical Oncology, 18(1), 70-76. [More Information]
  • Pollicino, C., Turner, S., Roos, D., O'Brien, P. (2005). Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain. Radiotherapy and Oncology, 76(3), 264-269. [More Information]
  • Denham, J., Steigler, A., Lamb, D., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al (2005). Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. The Lancet Oncology, 6(11), 841-850. [More Information]
  • Kneebone, A., Gebski, V., Hogendoorn, N., Turner, S. (2003). A randomised trial evaluating rigid immobilization for pelvic irradiation. International Journal of Radiation: Oncology - Biology - Physics, 56(4), 1105-1111.
  • Kneebone, A., Turner, S., Berry, M., Vachan, B., Gebski, V. (2003). Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. Journal of Medical Imaging and Radiation Oncology, 47(4), 422-427.
  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality following stronutium-89 therapy for mestatic prostate cancer. British Journal of Cancer, 24, 5-14.
  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. British Journal of Cancer, 84(3), 297-302.

Conferences

  • Thompson, S., Turner, S., Gebski, V. (2001). The IPSS: A Better Way of Measuring Urinary Morbidity from Prostate Brachytherapy? Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.

2013

  • Denham, J., Steigler, A., Tai, K., Joseph, D., Matthews, J., Atkinson, C., Spry, N., Turner, S., North, J., Christie, D., et al (2013). Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiotherapy and Oncology, 107(2), 123-128. [More Information]
  • Smith, A., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., et al (2013). The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(11), 2557-2564. [More Information]

2012

  • Hindson, B., Turner, S., Millar, J., Foroudi, F., Gogna, N., Skala, M., Kneebone, A., Christie, D., Lehman, M., Wiltshire, K., et al (2012). Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. Journal of Medical Imaging and Radiation Oncology, 56(1), 18-30. [More Information]
  • Ng, E., Woo, H., Turner, S., Leong, E., Jackson, M., Spry, N. (2012). The Influence of Testosterone Suppression and Recovery on Sexual Function in Men With Prostate Cancer: Observations From a Prospective Study in Men Undergoing Intermittent Androgen Suppression. The Journal of Urology, 187(6), 2162-2167. [More Information]

2011

  • Sundaresan, P., Turner, S., Kneebone, A., Pearse, M., Butow, P. (2011). Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03). Radiotherapy and Oncology, 101(3), 521-524. [More Information]
  • Denham, J., Steigler, A., Lamb, D., Joseph, D., Turner, S., Matthews, J., Atkinson, C., North, J., Christie, D., Spry, N., et al (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology, 12(5), 451-459. [More Information]

2010

  • Turner, S., Morgan, G., Palme, C., Veness, M. (2010). Metastatic cutaneous squamous cell carcinoma of the external ear: a high-risk cutaneous subsite. Journal of Laryngology and Otology, 124(1), 26-31. [More Information]

2006

  • Graham, P., Capp, A., Delaney, G., Goozee, G., Hickey, B., Turner, S., Browne, L., Milross, C., Wirth, A. (2006). A Pilot Randomised Comparison of Dexamethasone 96 mg vs 16 mg per day for Malignant Spinal-cord Compression Treated by Radiotherapy: TROG 01.05 Superdex Study. Clinical Oncology, 18(1), 70-76. [More Information]

2005

  • Pollicino, C., Turner, S., Roos, D., O'Brien, P. (2005). Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain. Radiotherapy and Oncology, 76(3), 264-269. [More Information]
  • Denham, J., Steigler, A., Lamb, D., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al (2005). Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. The Lancet Oncology, 6(11), 841-850. [More Information]

2003

  • Kneebone, A., Gebski, V., Hogendoorn, N., Turner, S. (2003). A randomised trial evaluating rigid immobilization for pelvic irradiation. International Journal of Radiation: Oncology - Biology - Physics, 56(4), 1105-1111.
  • Kneebone, A., Turner, S., Berry, M., Vachan, B., Gebski, V. (2003). Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. Journal of Medical Imaging and Radiation Oncology, 47(4), 422-427.

2001

  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality following stronutium-89 therapy for mestatic prostate cancer. British Journal of Cancer, 24, 5-14.
  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. British Journal of Cancer, 84(3), 297-302.
  • Thompson, S., Turner, S., Gebski, V. (2001). The IPSS: A Better Way of Measuring Urinary Morbidity from Prostate Brachytherapy? Royal Australian & New Zealand College of Radiologists, 52nd Annual Scientific Meeting.

To update your profile click here. For support on your academic profile contact .